Organic Sales Growth: 11% in Q1 2025. Volume Growth: 10% in Q1 2025. Adjusted EBITDA Margin: 38.3%, an increase of 3.1 percentage points year-on-year. Adjusted Gross Margin: 58.9%, an improvement of 330 basis points year-on-year. Diluted Adjusted Earnings Per Share: EUR 0.42, a 27% increase year-on-year. Free Cash Flow Before Acquisitions: EUR 68.1 million in Q1 2025. Food & Health Biosolutions Organic Sales Growth: 12% in Q1 2025. Food & Beverages Organic Sales Growth: 11% in Q1 2025. Human Health Organic Sales Growth: 13% in Q1 2025. Planetary Health Biosolutions Organic Sales Growth: 11% in Q1 2025. Household Care Organic Sales Growth: 12% in Q1 2025. Agriculture, Energy & Tech Organic Sales Growth: 10% in Q1 2025. Operating Cash Flow: EUR 106.4 million in Q1 2025. 2025 Full Year Organic Sales Growth Outlook: 5% to 8%. 2025 Full Year Adjusted EBITDA Margin Outlook: 37% to 38%. Warning! GuruFocus has detected 6 Warning Signs with NVZMF. Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Novonesis (Novozymes) B (NVZMF) reported a strong 11% organic sales growth in Q1 2025, driven by a 10% volume increase and 1% pricing contribution. The company achieved a 38.3% adjusted EBITDA margin, an increase of 3.1 percentage points compared to the previous year. Emerging markets showed robust performance with a 15% growth, while developed markets grew by 9%. Six new biosolutions were launched in Q1, with further acceleration of launches expected in the coming quarters. The acquisition of dsm-firmenich is expected to unlock further value in the core business, particularly in animal biosolutions, contributing to revenue growth and earnings accretion. Negative Points The exit from Russia and Belarus is expected to negatively impact full-year organic sales growth by around 1 percentage point. Currency headwinds are anticipated to affect the adjusted EBITDA margin, although the company maintains its guidance of 37% to 38%. The US market for Household Care is sensitive to down trading, and there is a cautious outlook for the full year due to potential changes in consumer order patterns. The EIA has lowered its forecast for US ethanol production from 1% growth to flat, which could impact the Agriculture, Energy & Tech division. Operating cash flow was affected by increased net working capital, mainly from lower trade payables and higher receivables, resulting in a lower free cash flow compared to the previous year. Q & A Highlights Q: Can you elaborate on the strong performance in Household Care and the impact of emerging market penetration? A: Ester Baiget, CEO, explained that the strong start to the year was anticipated, with no changes in customer order patterns. Emerging markets have shown strong growth, and penetration is expected to be sustainable throughout the year. Tina Sejersgard Fano, EVP of Planetary Health Biosolutions, added that the main growth driver is penetration, particularly in emerging markets, and the outlook includes some expected softness in the second half of the year. Story Continues Q: How is the growth in the dairy segment, particularly in China, and what are the expectations for Food & Beverages? A: Ester Baiget, CEO, noted double-digit growth in dairy across all regions, including China, driven by cheese and innovation. Claus Crone Fuglsang, Chief Scientific Officer, highlighted the innovation pipeline in dairy, including biopreservation and high-protein dairy solutions. The growth is expected to continue strongly, excluding the impact of exiting Russia and Belarus. Q: What is driving growth in the Human Health segment, and how does it compare to market growth rates? A: Amy Byrick, EVP of Human Health Biosolutions, stated that the segment is positioned to grow ahead of the market, which is around 6% globally. The focus is on high-growth categories like women's health, infant health, and mental health, supported by innovation and synergy launches. The healthcare practitioner channel in the US is particularly resilient. Q: Can you discuss the impact of macroeconomic uncertainty on your full-year organic growth guidance? A: Ester Baiget, CEO, acknowledged the strong start to the year with 11% growth in Q1. The guidance of 5% to 8% organic growth considers potential macroeconomic impacts, such as reduced consumer confidence and changes in bioethanol demand. The company's diversified portfolio and global presence provide resilience against these uncertainties. Q: How are you managing the impact of tariffs and currency fluctuations on profitability? A: Rainer Lehmann, CFO, explained that the company mitigates tariff impacts through a global manufacturing footprint and supply chain optimization. Currency fluctuations are expected to have a 0.5 to 0.75 percentage point impact on EBITDA margin, but operational performance remains strong, allowing the company to maintain its margin guidance. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
Novonesis (Novozymes) B (NVZMF) Q1 2025 Earnings Call Highlights: Strong Organic Growth and ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...